title: Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication.
abstract: The cellular alterations produced in cisplatin-resistant A2780 ovarian cancer cells (A2780/R) upon treatment with the cytotoxic organogold(III) complex Aubipyc were investigated in depth through a classical proteomic approach. We observed that A2780/R cell exposure to a cytotoxic concentration of Aubipyc for 24 hours results in a conspicuous number of alterations at the protein level that were carefully examined. Notably, we observed that several affected proteins belong to the glucose metabolism system further supporting the idea that the cytotoxic effects of Aubipyc in A2780/R cells are mostly mediated by an impairment of glucose metabolism in excellent agreement with previous observations on the parent cisplatin-sensitive cell line.
authors.affiliation: Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Viale Morgagni 50, Florence, Italy. tania.gamberi@unifi.it.
authors.forename: Tania
authors.initials: T
authors.lastname: Gamberi
authors.forename: Francesca
authors.initials: F
authors.lastname: Magherini
authors.forename: Tania
authors.initials: T
authors.lastname: Fiaschi
authors.forename: Ida
authors.initials: I
authors.lastname: Landini
authors.forename: Lara
authors.initials: L
authors.lastname: Massai
authors.forename: Elisa
authors.initials: E
authors.lastname: Valocchia
authors.forename: Laura
authors.initials: L
authors.lastname: Bianchi
authors.forename: Luca
authors.initials: L
authors.lastname: Bini
authors.forename: Chiara
authors.initials: C
authors.lastname: Gabbiani
authors.forename: Stefania
authors.initials: S
authors.lastname: Nobili
authors.forename: Enrico
authors.initials: E
authors.lastname: Mini
authors.forename: Luigi
authors.initials: L
authors.lastname: Messori
authors.forename: Alessandra
authors.initials: A
authors.lastname: Modesti
mesh_terms: D015082:2,2'-Dipyridyl / Q000031:analogs & derivatives* / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D015180:Electrophoresis, Gel, Two-Dimensional; D005260:Female; D006801:Humans; D050607:Organogold Compounds / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D020543:Proteome / Q000032:analysis / Q000378:metabolism*; D015203:Reproducibility of Results
chemical_list: D000970:Antineoplastic Agents; D050607:Organogold Compounds; D020543:Proteome; C453480:hydroxo(6-(1,1-dimethylbenzyl)-2,2'-bipyridine)gold(III); D015082:2,2'-Dipyridyl; D002945:Cisplatin